Alto Neuroscience ANRO Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Returns | |||
| Return on equity | -41.8%— | —— | |
| Return on assets | -34.9%+11.6pp | -46.5%— | |
| Liquidity | |||
| Current ratio | 15.7×-1.2× | 16.9×+1.7× | |
| Quick ratio | 15.7×-1.2× | 16.9×+1.7× | |
| Cash ratio | 15.6×-1.2× | 16.9×+2.1× | |
| Leverage | |||
| Debt-to-equity | 0.1×0.0× | 0.1×— | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -26.9×+23.0× | -49.9×-22.3× | |
| Per Share | |||
| Book value per share | $5.24-14.9% | $6.16+132% | |
| Valuation | |||
| Market capitalization | $887.88M+1,358% | $114.08M— | |
| Enterprise value | $644.49M-958% | -$39.01M— | |
| Price / book | 3.6×+3.2× | 0.8×— | |
| Free cash flow yield | -7.1%+83.0pp | -43.4%— | |
| Earnings yield | -8.4%+95.4pp | -53.8%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Alto Neuroscience's ratios come from?
- Every ratio is computed from Alto Neuroscience's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.